ClinicalTrials.gg
CompletedNCT07711444Updated Jul 21, 2026

The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms

An interventional study of Eicosapentaenoic acid (omega-3 fatty acid) and Specialized Pro-Resolving Lipid Mediator in COVID - 19 and Depression - Major Depressive Disorder, sponsored by National Science and Technology Council, Taiwan. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2024, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in COVID-19 with a site in Taiwan — 12 open to participants now, 13 under way, 7 of them phase 3. COVID-19 · Taiwan.

Enrollment
44th of 56
54 · median 137
Started
2024
with 6 others
No phase
16 of 78
1 open now
Registered
78th of 78
by date

Among the 78 studies in COVID-19 with a site in Taiwan, this one is the 44th largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2024, is one of 16 with no phase, and was the 78th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

12 of the 78 studies in COVID-19 with a site in Taiwan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in COVID-19 with a site in Taiwan, or all of them as a file.
02

Study summary

Researchers conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients. Researchers planned to enroll 240 eligible participants from various general and psychiatric hospitals in Taiwan. The focus was on evaluating the therapeutic impact and potential side effects of administering 3 g/day of EPA or 1.67 mg/day of SPMs on symptoms of depression in these patients. This consolidated approach aims to provide comprehensive insights into the efficacy of EPA and SPM treatments in Long COVID cases, addressing crucial mental health aspects.

03

Conditions studied

  • COVID - 19
  • Depression - Major Depressive Disorder

Keywords

  • SPM
  • EPA
  • Depression
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed SARS-CoV-2 infection by PCR, documented positive test, or clinician diagnosis
  • Meeting CDC criteria for Post-COVID Conditions (Long COVID) as the presence of new, returning, or ongoing symptoms ≥4 weeks after confirmed SARS-CoV-2 infection
  • Hamilton Depression Rating Scale (HAMD-21) score ≥18 at baseline
  • Stable antidepressant treatment for ≥4 weeks or no current antidepressant use; and
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Current or past six-month diagnosis of psychotic disorder, bipolar disorder, substance use disorder, or other major psychiatric conditions based on ICD-10 or criteria
  • Significant neurological or medical comorbidities (eg, epilepsy, traumatic brain injury, disease, cancer), acute infections, or laboratory abnormalities
  • Regular use of SPM or EPA supplementation >0·5 g/day
  • Known allergy or intolerance to omega-3 fatty acids or SPMs; and
  • Requirement for inpatient psychiatric care due to acute suicide risk
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Eicosapentaenoic acid (EPA)

    Eicosapentaenoic acid (EPA) at a total daily dose of 3 g, administered as six capsules

    Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid)

  • Experimental
    Specialized pro-resolving mediators (SPMs)

    SPM at a total daily dose of 1.67 g, administered as six capsules

    Dietary Supplement: Specialized Pro-Resolving Lipid Mediator

  • Placebo comparator
    Placebo

    soybean oil

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementEicosapentaenoic AcidStudies of Eicosapentaenoic AcidEicosapentaenoic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A total daily dose of 3 g, administered as six capsules

    Also known as: EPA

  • Dietary supplementSpecialized Pro-Resolving Lipid Mediator

    A total daily dose of 1.67 g, administered as six capsules

    Also known as: SPM

  • Dietary supplementPlacebo

    Six capsules containing soybean oil daily

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale (HAMD)

    Adult depressive symptoms were assessed using the 21-item HAMD at baseline (week 0) and at weeks 1, 2, 4, 8, and 12.

    Time frame: (week 0) and at weeks 1, 2, 4, 8, and 12

Secondary outcomes

  1. Erythrocyte Omega-3 Polyunsaturated Fatty Acids

    Peripheral blood samples were collected at baseline and at the end of the 12-week intervention period using EDTA-containing tubes for erythrocyte fatty acid analysis

    Time frame: Week 0 and Week 12

07

Study locations

1 site
  • Mind-Body Interface Research Center (MBI Lab & Care)
    Taichung, Taichung 404, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2025, 18 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 18 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Jun 1, 2024
Primary completionActual
Dec 1, 2025
CompletionActual
Jun 1, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711444
Lead sponsor
National Science and Technology Council, Taiwan
Responsible party
Kuan-Pin (Professor, National Science and Technology Council, Taiwan) — Principal investigator
First posted
Jul 17, 2026
Start date
Jun 1, 2024
Primary completion
Dec 1, 2025
Completion
Jun 1, 2026
Last update
Jul 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eicosapentaenoic Acid

Start the discussion